The in vitro protective effects of the three novel nanomolar reversible inhibitors of human cholinesterases against irreversible inhibition by organophosphorous chemical warfare agents

Levy, 2000, Therapeutic versus prophylactic treatment strategies against nerve-agent induced brain injuries, Proc. Med. Def. Biosci. Rev. US-AMRMC, Balt., 280 Eyer, 2003, The current status of oximes in the treatment of OP poisoning—comparing two regimes. Rome: european Association of Poisons Centres and Clinical Toxicologists, J. Toxicol. Clin. Toxicol., 41, 441 Worek, 2004, Kinetic analysis of interactions between human acetylcholinesterase, structurally different organophosphorus compounds and oximes, Biochem. Pharmacol., 68, 2237, 10.1016/j.bcp.2004.07.038 Ashani, 2003, Inhibition of cholinesterases with cationic phosphonyl oximes highlights distinctive properties of the charged pyridine groups of quaternary oxime reactivators, Biochem. Pharmacol., 66, 191, 10.1016/S0006-2952(03)00204-1 Kiderlen, 2005, Formation and disposition of diethylphosphoryl-obidoxime, a potent anticholinesterase that is hydrolyzed by human paraoxonase (PON1), Biochem. Pharmacol., 69, 1853, 10.1016/j.bcp.2005.04.003 Berry, 1970, The use of carbamates and atropine in the protection of animals against poisoning by 1, 2, 2-trimethylpropyl methylphosphonofluoridate, Biochem. Pharmacol., 19, 927, 10.1016/0006-2952(70)90256-X Dirnhuber, 1979, The protection of primates against soman poisoning by pretreatment with pyridostigmine, J. Pharm. Pharmacol., 31, 295, 10.1111/j.2042-7158.1979.tb13504.x Harris, 1980, The effects of pretreatments with carbamates, atropine and mecamylamine on survival and on soman-induced alterations in rat and rabbit brain acetylcholine, Life Sci., 26, 1885, 10.1016/0024-3205(80)90617-7 Leadbeater, 1985, Treatment of poisoning by soman, Fundam. Appl. Toxicol., 5, S225, 10.1016/0272-0590(85)90132-0 Lennox, 1992, Successful pretreatment/therapy of soman, sarin and VX intoxication, Drug Chem. Toxicol., 15, 271, 10.3109/01480549209014157 Meshulam, 1995, Prophylactic transdermal treatment with physostigmine and scopolamine against soman intoxication in Guinea‐pigs, J. Appl. Toxicol., 15, 263, 10.1002/jat.2550150406 Meshulam, 2001, Prophylaxis against organophosphate poisoning by sustained release of scopolamine and physostigmine, J. Appl. Toxicol. An Int. J., 21, S75, 10.1002/jat.815 Kim, 2005, Protection by a transdermal patch containing physostigmine and procyclidine of soman poisoning in dogs, Eur. J. Pharmacol., 525, 135, 10.1016/j.ejphar.2005.09.052 Albuquerque, 2006, Effective countermeasure against poisoning by organophosphorus insecticides and nerve agents, Proc. Natl. Acad. Sci. U.S.A., 103, 13220, 10.1073/pnas.0605370103 Lallement, 2002, Review of the value of huperzine as pretreatment of organophosphate poisoning, Neurotoxicology, 23, 1, 10.1016/S0161-813X(02)00015-3 Petroianu, 2013, Usefulness of administration of non‐organophosphate cholinesterase inhibitors before acute exposure to organophosphates: assessment using paraoxon, J. Appl. Toxicol., 33, 894, 10.1002/jat.2760 Vitorović-Todorović, 2012, The 3D-QSAR study of 110 diverse, dual binding, acetylcholinesterase inhibitors based on alignment independent descriptors (GRIND-2). The effects of conformation on predictive power and interpretability of the models, J. Mol. Graph. Model., 38, 194, 10.1016/j.jmgm.2012.08.001 Vitorović-Todorović, 2010, 4-Aryl-4-oxo-N-phenyl-2-aminylbutyramides as acetyl-and butyrylcholinesterase inhibitors. Preparation, anticholinesterase activity, docking study, and 3D structure–activity relationship based on molecular interaction fields, Bioorg. Med. Chem., 18, 1181, 10.1016/j.bmc.2009.12.042 Vitorović-Todorović, 2014, Structural modifications of 4-aryl-4-oxo-2-aminylbutanamides and their acetyl-and butyrylcholinesterase inhibitory activity. Investigation of AChE–ligand interactions by docking calculations and molecular dynamics simulations, Eur. J. Med. Chem., 81, 158, 10.1016/j.ejmech.2014.05.008 Ellman, 1961, A new and rapid colorimetric determination of acetylcholinesterase activity, Biochem. Pharmacol., 7, 88, 10.1016/0006-2952(61)90145-9 Worek, 2012, Reactivation kinetics of a series of related bispyridinium oximes with organophosphate-inhibited human acetylcholinesterase—structure–activity relationships, Biochem. Pharmacol., 83, 1700, 10.1016/j.bcp.2012.03.002 Worek, 1999, Improved determination of acetylcholinesterase activity in human whole blood, Clin. Chim. Acta, 288, 73, 10.1016/S0009-8981(99)00144-8 Forsberg, 1984, Kinetics for the inhibition of acetylcholinesterase from the electric eel by some organophosphates and carbamates, Eur. J. Biochem., 140, 153, 10.1111/j.1432-1033.1984.tb08079.x Aurbek, 2006, Analysis of inhibition, reactivation and aging kinetics of highly toxic organophosphorus compounds with human and pig acetylcholinesterase, Toxicology, 224, 91, 10.1016/j.tox.2006.04.030 Cheung, 2012, Structures of human acetylcholinesterase in complex with pharmacologically important ligands, J. Med. Chem., 55, 10282, 10.1021/jm300871x Waterhouse, 2018, SWISS-MODEL: homology modelling of protein structures and complexes, Nucleic Acids Res., 46, W296, 10.1093/nar/gky427 Halgren, 1999, MMFF VI. MMFF94s option for energy minimization studies, J. Comput. Chem., 20, 720, 10.1002/(SICI)1096-987X(199905)20:7<720::AID-JCC7>3.0.CO;2-X Stewart, 2013, Optimization of parameters for semiempirical methods VI: more modifications to the NDDO approximations and re-optimization of parameters, J. Mol. Model., 19, 1, 10.1007/s00894-012-1667-x Dolinsky, 2007, PDB2PQR: expanding and upgrading automated preparation of biomolecular structures for molecular simulations, Nucleic Acids Res., 35, W522, 10.1093/nar/gkm276 Trott, 2010, Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading, J. Comput. Chem., 31, 455 Korb, 2006, PLANTS: application of ant colony optimization to structure-based drug design, 247 Pedretti, 2004, VEGA – an open platform to develop chemo-bio-informatics applications, using plug-in architecture and script programming, J. Comput. Aided Mol. Des., 18, 167, 10.1023/B:JCAM.0000035186.90683.f2 Jo, 2008, CHARMM-GUI: a web-based graphical user interface for CHARMM, J. Comput. Chem., 29, 1859, 10.1002/jcc.20945 Huang, 2016, CHARMM36m: an improved force field for folded and intrinsically disordered proteins, Nat. Methods, 14, 71, 10.1038/nmeth.4067 Vanommeslaeghe, 2009, CHARMM general force field: a force field for drug-like molecules compatible with the CHARMM all-atom additive biological force fields, J. Comput. Chem., 31, 671 Phillips, 2005, Scalable molecular dynamics with NAMD, J. Comput. Chem., 26, 1781, 10.1002/jcc.20289 Humphrey, 1996, VMD: visual molecular dynamics, J. Mol. Graph., 14, 33, 10.1016/0263-7855(96)00018-5 Bermudez, 2015, Structural characteristics of the allosteric binding site represent a key to subtype selective modulators of muscarinic acetylcholine receptors, Mol. Inform., 34, 526, 10.1002/minf.201500025 Bock, 2016, Ligand binding ensembles determine graded agonist efficacies at a G protein-coupled receptor, J. Biol. Chem., 291, 16375, 10.1074/jbc.M116.735431 Wolber, 2005, LigandScout: 3-D pharmacophores derived from protein-bound ligands and their use as virtual screening filters, J. Chem. Inf. Model., 45, 160, 10.1021/ci049885e Radić, 1999, The influence of peripheral site ligands on the reaction of symmetric and chiral organophosphates with wildtype and mutant acetylcholinesterases, Chem. Biol. Interact., 119, 111, 10.1016/S0009-2797(99)00019-8 Petroianu, 2000, L‐lactate protects in vitro acetylcholinesterase (AChE) from inhibition by paraoxon (E 600), J. Appl. Toxicol. An Int. J., 20, 249, 10.1002/1099-1263(200007/08)20:4<249::AID-JAT652>3.0.CO;2-X Petroianu, 2003, In vitro protection of red blood cell acetylcholinesterase by metoclopramide from inhibition by organophosphates (paraoxon and mipafox), J. Appl. Toxicol. An Int. J., 23, 447, 10.1002/jat.936 Petroianu, 2005, Weak inhibitors protect cholinesterases from strong inhibitors (paraoxon): in vitro effect of ranitidine, J. Appl. Toxicol. An Int. J., 25, 60, 10.1002/jat.1036 Petroianu, 2006, Ranitidine in acute high‐dose organophosphate exposure in rats: effect of the time‐point of administration and comparison with pyridostigmine, Basic Clin. Pharmacol. Toxicol., 99, 312, 10.1111/j.1742-7843.2006.pto_215.x Nizami, 2016, Molecular insight on the binding of NNRTI to K103N mutated HIV-1 RT: molecular dynamics simulations and dynamic pharmacophore analysis, Mol. Biosyst., 12, 3385, 10.1039/C6MB00428H Mortier, 2015, The impact of molecular dynamics on drug design: applications for the characterization of ligand-macromolecule complexes, Drug Discov. Today, 20, 686, 10.1016/j.drudis.2015.01.003